Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.52
PCRX's Cash to Debt is ranked higher than
70% of the 1152 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. PCRX: 1.52 )
PCRX' s 10-Year Cash to Debt Range
Min: 0.73   Max: No Debt
Current: 1.52

Equity to Asset 0.53
PCRX's Equity to Asset is ranked higher than
65% of the 1034 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. PCRX: 0.53 )
PCRX' s 10-Year Equity to Asset Range
Min: -0.73   Max: 0.59
Current: 0.53

-0.73
0.59
F-Score: 7
Z-Score: 11.43
M-Score: -1.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2.61
PCRX's Operating margin (%) is ranked higher than
56% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. PCRX: -2.61 )
PCRX' s 10-Year Operating margin (%) Range
Min: -325.77   Max: -2.61
Current: -2.61

-325.77
-2.61
Net-margin (%) -6.94
PCRX's Net-margin (%) is ranked higher than
55% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.10 vs. PCRX: -6.94 )
PCRX' s 10-Year Net-margin (%) Range
Min: -300.62   Max: -6.94
Current: -6.94

-300.62
-6.94
ROE (%) -12.44
PCRX's ROE (%) is ranked higher than
54% of the 1129 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. PCRX: -12.44 )
PCRX' s 10-Year ROE (%) Range
Min: -119.34   Max: -12.92
Current: -12.44

-119.34
-12.92
ROA (%) -5.46
PCRX's ROA (%) is ranked higher than
56% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. PCRX: -5.46 )
PCRX' s 10-Year ROA (%) Range
Min: -67.11   Max: -5.53
Current: -5.46

-67.11
-5.53
ROC (Joel Greenblatt) (%) -7.46
PCRX's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.14 vs. PCRX: -7.46 )
PCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -291.9   Max: -7.31
Current: -7.46

-291.9
-7.31
Revenue Growth (3Y)(%) 80.60
PCRX's Revenue Growth (3Y)(%) is ranked higher than
99% of the 932 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. PCRX: 80.60 )
PCRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -67   Max: 80.6
Current: 80.6

-67
80.6
EPS Growth (3Y)(%) -47.10
PCRX's EPS Growth (3Y)(%) is ranked higher than
51% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. PCRX: -47.10 )
PCRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.6   Max: -47.1
Current: -47.1

-68.6
-47.1
» PCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PCRX Guru Trades in Q1 2014

Ron Baron 17,100 sh (+163.28%)
Jim Simons 171,500 sh (+139.86%)
Mariko Gordon 1,371,042 sh (+5.13%)
RS Investment Management 285,016 sh (-13.35%)
Steven Cohen 82,506 sh (-20.36%)
» More
Q2 2014

PCRX Guru Trades in Q2 2014

Joel Greenblatt 9,486 sh (New)
Ron Baron 154,393 sh (+802.88%)
Jim Simons Sold Out
RS Investment Management 284,033 sh (-0.34%)
Mariko Gordon 1,132,552 sh (-17.39%)
» More
Q3 2014

PCRX Guru Trades in Q3 2014

Paul Tudor Jones 9,094 sh (New)
Jim Simons 39,800 sh (New)
RS Investment Management 689,193 sh (+142.65%)
Joel Greenblatt 6,946 sh (-26.78%)
Mariko Gordon 814,470 sh (-28.09%)
Ron Baron 62,139 sh (-59.75%)
» More
Q4 2014

PCRX Guru Trades in Q4 2014

Ken Fisher 4,800 sh (New)
George Soros 87,000 sh (New)
Ron Baron 67,088 sh (+7.96%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
RS Investment Management 594,323 sh (-13.77%)
Mariko Gordon 689,628 sh (-15.33%)
Jim Simons 9,800 sh (-75.38%)
» More
» Details

Insider Trades

Latest Guru Trades with PCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pacira Pharmaceuticals Inc

Baron Funds Comments on Pacira Pharmaceuticals - Mar 05, 2014

Pacira Pharmaceuticals, Inc. (PCRX) is a vertically integrated (IP to manufacturing) pharmaceutical company. Its main line of business is the sale of a drug called EXPAREL, which was approved by the FDA in October 2011 and launched in the U.S. in April 2012. EXPAREL is a pain control drug (using slow release bupivacaine) injected directly into the wound/cut site during a surgical procedure, prior to closing the incision. It is also being studied for use as a nerve block agent for additional procedures. Bupivacaine is a well-known drug that has been used for decades during surgery. Its safety profile is well understood. The key advantage of EXPAREL over generic bupivacaine is that it incorporates a proprietary time-release "wrapper" called DepoFoam that lets the pain relief delivered by bupivacaine last for up to three days post-surgery. This enables reduced usage of dangerous opiates and other treatments, such as pain balls. In the end, we believe that based on clinical studies, EXPAREL is cheaper, safer and more effective than current pain management practices. We believe that EXPAREL has significant IP protection and has limited potential competitors.

Uptake among large hospital formularies has been brisk, and EXPAREL has been at least initially purchased at over 75% of the top 100 hospitals in the U.S. and most of the top 500 hospitals.Yet penetration of the potential $40 million procedure market is still minimal. Most current sales are for soft tissue procedures, but orthopedic studies also look promising. EXPAREL did about $14.5 million in sales in 2012, which grew to about $76 million in 2013 based on information recently released by the company. The fourth quarter annualized run rate of the drug is over $120 million.This means that the company is going to have to expand capacity from its current $100 million volume plant. It has built capacity for up to $400 million in sales, and is awaiting what we believe will be near term approval from the FDA on the plant. We believe EXPAREL represents a worldwide market opportunity of potentially billions of dollars and that it is just at the start of its overall volume penetration.Additionally, the company has longer term plans to use its DepoFoam "wrapper" technology on other drugs, including methotrexate (for rheumatoid arthritis). If this massive opportunity set is properly exploited, we believe that Pacira could become a billion dollar revenue company within a few years, and earnings per share could ultimately exceed $10 on EXPAREL alone. At a current price of $65, shares trade at only 6.5x this level, and it's possible that they could trade at 15-20x if growth hits our expectations.

From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 commentary.

Check out Ron Baron latest stock trades

Top Ranked Articles about Pacira Pharmaceuticals Inc

Mariko Gordon's First Quarter Top Five
“Thrift, fearlessness, resilience, hard work, intellectual curiosity and an ability to take and avoid risk are in my blood—a perfect pedigree for a money manager.” - Mariko Gordon

Mariko Gordon is one of the newest gurus introduced to the exclusive list of investment gurus followed by GuruFocus. Gordon founded Daruma Capital Management in 1995, after having worked with Valenzuela Capital Management as well as the small-cap guru Chuck Royce and his fund, Royce & Associates. Currently Mariko Gordon is the CEO and CIO of her fund Daruma Asset Management. Read more...

Ratios

vs
industry
vs
history
Forward P/E 23.92
PCRX's Forward P/E is ranked higher than
83% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PCRX: 23.92 )
N/A
P/B 17.80
PCRX's P/B is ranked lower than
59% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. PCRX: 17.80 )
PCRX' s 10-Year P/B Range
Min: 3.47   Max: 73.22
Current: 17.8

3.47
73.22
P/S 15.20
PCRX's P/S is ranked lower than
65% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. PCRX: 15.20 )
PCRX' s 10-Year P/S Range
Min: 0.39   Max: 30.44
Current: 15.2

0.39
30.44
PFCF 1063.10
PCRX's PFCF is ranked higher than
68% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PCRX: 1063.10 )
PCRX' s 10-Year PFCF Range
Min: 1058.13   Max: 1466.63
Current: 1063.1

1058.13
1466.63
POCF 121.53
PCRX's POCF is ranked higher than
68% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.91 vs. PCRX: 121.53 )
PCRX' s 10-Year POCF Range
Min: 120.93   Max: 709.6
Current: 121.53

120.93
709.6
EV-to-EBIT -586.26
PCRX's EV-to-EBIT is ranked lower than
51% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.18 vs. PCRX: -586.26 )
PCRX' s 10-Year EV-to-EBIT Range
Min: -809   Max: -1.4
Current: -586.26

-809
-1.4
Current Ratio 1.53
PCRX's Current Ratio is ranked higher than
61% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. PCRX: 1.53 )
PCRX' s 10-Year Current Ratio Range
Min: 0.87   Max: 4.3
Current: 1.53

0.87
4.3
Quick Ratio 1.32
PCRX's Quick Ratio is ranked higher than
65% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. PCRX: 1.32 )
PCRX' s 10-Year Quick Ratio Range
Min: 0.75   Max: 3.45
Current: 1.32

0.75
3.45
Days Inventory 97.13
PCRX's Days Inventory is ranked higher than
81% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. PCRX: 97.13 )
PCRX' s 10-Year Days Inventory Range
Min: 31.07   Max: 105.63
Current: 97.13

31.07
105.63
Days Sales Outstanding 41.30
PCRX's Days Sales Outstanding is ranked higher than
90% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. PCRX: 41.30 )
PCRX' s 10-Year Days Sales Outstanding Range
Min: 29.85   Max: 67.76
Current: 41.3

29.85
67.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1661.00
PCRX's Price/Net Cash is ranked higher than
78% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PCRX: 1661.00 )
PCRX' s 10-Year Price/Net Cash Range
Min: 20.12   Max: 1773.2
Current: 1661

20.12
1773.2
Price/Net Current Asset Value 90.30
PCRX's Price/Net Current Asset Value is ranked higher than
71% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PCRX: 90.30 )
PCRX' s 10-Year Price/Net Current Asset Value Range
Min: 12.54   Max: 54.06
Current: 90.3

12.54
54.06
Price/Tangible Book 20.40
PCRX's Price/Tangible Book is ranked lower than
54% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. PCRX: 20.40 )
PCRX' s 10-Year Price/Tangible Book Range
Min: 5.09   Max: 99.99
Current: 20.4

5.09
99.99
Price/Median PS Value 0.90
PCRX's Price/Median PS Value is ranked higher than
91% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. PCRX: 0.90 )
PCRX' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 1.37
Current: 0.9

0.51
1.37
Earnings Yield (Greenblatt) -0.20
PCRX's Earnings Yield (Greenblatt) is ranked higher than
56% of the 1148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. PCRX: -0.20 )
PCRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.7   Max: 0
Current: -0.2

-0.7
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:82P.Germany,
Pacira Pharmaceuticals Inc was incorporated in Delaware under the name Blue Acquisition Corp. in December 2006 and changed its name to Pacira, Inc. in June 2007. The Company is a pharmaceutical company engaged in the development, commercialization and manufacture of proprietary pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. As of December 31, 2013, its commercial stage products are EXPAREL and DepoCyt. EXPAREL is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia and was approved by the FDA on October 28, 2011. The Company commercially launched EXPAREL in April 2012. It ship EXPAREL directly to the end user based on orders placed to wholesalers or directly to the Company and have no product held by wholesalers. DepoCyt is a sustained release liposomal formulation of the chemotherapeutic agent cytarabine and is indicated for the intrathecal treatment of lymphomatous meningitis. DepoCyt was granted accelerated approval by the FDA in 1999 and full approval in 2007. The Company sells DepoCyt to its commercial partners located in the U.S. and Europe. The Company's trademarks include Pacira, EXPAREL, DepoCyt and DepoCyte. The Company's customers are AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company. Its competitors include organizations such as multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and generic drug companies. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling, release and disposal of, and exposure to, these hazardous materials. In addition to regulations in the United States, it is subject to various foreign regulations governing clinical trials and the commercial sales and distribution of its products.
» More Articles for PCRX

Headlines

Articles On GuruFocus.com
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Pacira Pharmace Nov 28 2014 
Mariko Gordon's First Quarter Top Five May 15 2014 
Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 
comment on PCRX Mar 15 2013 
Weekly CFO Buys Highlight: PCRX, UGI, MIG, GLT, IOSP Feb 27 2011 
Weekly CFO Buys Highlight: REFR, UGI, PCRX, NOIZ Feb 21 2011 
Pacira Pharmaceuticals Inc. (PCRX) CFO James S Scibetta buys 5,000 Shares Feb 16 2011 
Pacira Pharmaceuticals Inc. (PCRX) CEO David M Stack buys 5,000 Shares Feb 11 2011 

More From Our Partners
Pacira Down on Subpoena on Exparel Marketing Issues - Analyst Blog Apr 17 2015 - ZACKS

More From Other Websites
Nasdaq stocks posting largest percentage decreases Apr 27 2015
Lifshitz & Miller Law Firm Announces Investigation of AudioEye, Inc., Cellular Biomedicine Group... Apr 27 2015
Pacira Down on Subpoena on Exparel Marketing Issues - Analyst Blog Apr 17 2015
Pacira Pharmaceuticals (PCRX) Falls: Stock Goes Down 9.7% - Tale of the Tape Apr 17 2015
Philip Morris and Netflix are big market movers Apr 16 2015
Glancy Binkow & Goldberg LLP Investigates Claims on Behalf of Pacira Pharmaceuticals Shareholders Apr 16 2015
The government is asking questions about this pharma company's painkiller and now the stock is... Apr 16 2015
Pacira Subpoenaed by Department of Justice Apr 16 2015
Pacira Pharmaceuticals (PCRX) Stock Declines Today Following DOJ Subpoena Apr 16 2015
Bernstein Liebhard LLP Investigates Claims On Behalf Of Holders Of Pacira Pharmaceuticals Stock Apr 16 2015
PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Apr 16 2015
Pacira Receives Subpoena from the U.S. Department of Justice Apr 16 2015
Pacira Announces Encouraging Data on Lead Drug Exparel - Analyst Blog Apr 13 2015
Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and... Apr 13 2015
Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and... Apr 13 2015
Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control... Apr 10 2015
Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control... Apr 10 2015
Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following... Mar 26 2015
Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following... Mar 26 2015
New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and... Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK